Strategy: focus on targets and indications with strong biological rationale

Historically, drug discovery in disorders of brain development (DBDs) has been unproductive, largely due to the lack of mechanistic understanding of these disorders, as well as absence of predictive animal models.  Recently, research by Seaside's founders has provided the first truly compelling understanding of specific mechanisms underlying DBDs.

Seaside's first program is derived from breakthrough research regarding fragile X syndrome (FXS), a disorder caused by a single abnormal gene (FMR1) and the most common known genetic cause of autism. Since FXS is caused by malfunction of a single gene, it has been possible to develop relevant animal models lacking this gene and displaying many of the aberrant behaviors seen in humans.  The discovery that abnormal function in these animals can be normalized by treatment with a novel class of of neurotransmitter modulators suggests that compounds in this class could be effective treatments for humans with FXS, autism, and other DBDs.

To assure that we assemble the assets and resources necessary for success, we have developed a unique business model emphasizing strategic collaborations with pharmaceutical and biotechnology companies, research institutions, government agencies, foundations and patient advocacy groups.

Next: Scientific Advisory Board »